SCHEMBL4347336

SCHEMBL4347336

Cc1ccc(C=C2SC(N3CCOCC3)=NC2=O)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.79
RAB9A P51151 3/20 0.77
ALOX5 P09917 2/20 0.69
ALDH1A1 P00352 8/20 0.69
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
SMN1; SMN2 Q16637 5/20 0.69
PSMD14 O00487 1/20 0.69
LMNA P02545 1/20 0.69
NPSR1 Q6W5P4 2/20 0.65
HPGD P15428 1/20 0.65
CYP1A2 P05177 1/20 0.62
CYP2C19 P33261 1/20 0.62
KDM4E B2RXH2 1/20 0.62
GAA P10253 1/20 0.62
MAPK1 P28482 1/20 0.59
HTT P42858 1/20 0.59
NPC1 O15118 2/20 0.58
IDE P14735 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347335 1.00 MAPT (0.79) MAPTRAB9AALOX5ALDH1A1MEN1
Bromide SCHEMBL4357476 0.99 MAPT (0.77) MAPTRAB9AALOX5ALDH1A1MEN1
Bromide SCHEMBL4357470 0.99 MAPT (0.77) MAPTRAB9AALOX5ALDH1A1MEN1
SCHEMBL4358837 0.88 MAPT (1.00) MAPTRAB9AALOX5ALDH1A1MEN1
SCHEMBL4358838 0.88 MAPT (1.00) MAPTRAB9AALOX5ALDH1A1MEN1
SCHEMBL4358730 0.87 MEN1 (0.65) MAPTRAB9AALOX5ALDH1A1MEN1
SCHEMBL4362311 0.87 ENPP2 (0.69) MAPTRAB9AALDH1A1MEN1KMT2A
SCHEMBL4352377 0.87 DCTPP1 (0.74) MAPTRAB9AALDH1A1MEN1KMT2A
SCHEMBL4357214 0.87 KMT2A (0.65) MAPTRAB9AALOX5ALDH1A1MEN1
SCHEMBL4352381 0.87 DCTPP1 (0.74) MAPTRAB9AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885RAB9A 3151/4885ALOX5 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.